Publications by authors named "J P Courreges"
Risk assessment of gastrointestinal stromal tumor (GIST) according to the AFIP/Miettinen classification and mutational profiling are major tools for patient management. However, the AFIP/Miettinen classification depends heavily on mitotic counts, which is laborious and sometimes inconsistent between pathologists. It has also been shown to be imperfect in stratifying patients.
View Article and Find Full Text PDFArticle Synopsis
- Since 2010, doctors in France have been collecting and studying cases of sarcomas and related tumors to better understand their numbers and types.
- Between 2013 and 2016, they found over 25,000 patients with different types of sarcomas, and the overall number was higher than they expected.
- The findings suggest that rare tumors are less likely to be included in clinical studies, which help create new treatments for these diseases.
Article Synopsis
- * Desmoid-type fibromatosis of the breast (DFB) makes up about 0.2% of breast tumors and is challenging to diagnose due to similarities with other tumors, necessitating precise genetic analysis for accurate identification.
- * A study revealed that DFB shows a unique mutation pattern, with a higher rate of APC mutations compared to other DF types, and combining Sanger and next-generation sequencing methods improved the detection rate of mutations, enhancing diagnosis and understanding of DFB's development.
Introduction: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs.
View Article and Find Full Text PDFPurpose: The optimal management of rare tumours (i.e. from accurate diagnosis to management in reference centres) is a public health challenge.
View Article and Find Full Text PDF